LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and determine the maximum safe dose of an
experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer. We have
identified hedgehog dysregulation as a novel mechanism for hepatocarcinogenesis and hepatic
fibrosis/cirrhosis. Therefore, we hypothesize that the hedgehog inhibitor may be an ideal
drug target for treating both hepatocellular carcinoma (HCC) and Child-Pugh A cirrhosis
(CPA).